USA flag logo/image

An Official Website of the United States Government

Vision restoration with photoswitch technology

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96141
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
EY019811
Solicitation Year:
N/A
Solicitation Topic Code:
NEI
Solicitation Number:
N/A
Small Business Information
PHOTOSWITCH BIOSCIENCES, INC.
1600 ADAMS DR MENLO PARK, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Vision restoration with photoswitch technology
Agency: HHS
Contract: 1R43EY019811-01A1
Award Amount: $374,532.00
 

Abstract:

DESCRIPTION (provided by applicant): Retinitis Pigmentosa (RP) is an inherited disease of the eye that robs its victims of vision. The loss of vision is caused by the degeneration of the rods and cones of the retina while other cells in the retina remain alive. RD is a relatively rare disease, affecting approximately 100,000 people in the US. Approximately 20% of children in schools for the blind suffer from RP. Clearly, the disastrous consequences of RP provide justification for intense research into the causes and potential therapies. Due to the polygenic nature of RP, it does not lend itself to gene therapy or targeted therapeutics. Although some successes in vision restoration using gene therapy have been reported, it is highly unlikely that such therap y will be approved and adopted by the medical community in the near future. An alternative approach to vision restoration for patients with RP, which does not involve gene therapy, is proposed in this Phase I SBIR application where the remaining cells in t he damaged retina are made into photosensitive cells using small molecules called photoswitches . Photoswitches could, in theory, provide resolution approximately a thousand times greater than that of competing video camera prosthetics and will be far les s invasive. The four Specific Aims for the first steps along the pathway to an approved therapeutic are (1) Determine which of the many cells in the retina are rendered light-sensitive by the injection of photoswitches into the eyes of blind mice; (2) Demo nstrate light-sensitivity in intact mutant blind mice using non-invasive electrophysiological approaches; (3) Demonstrate light-dependent behavior in genetically blind mice after photoswitch treatment; and (4) Determine the optimal parameters for maintaini ng light-sensitivity in mutant blind mice. The successful completion of this feasibility project will provide justification for the further pursuit of this therapeutic approach to blindness. PUBLIC HEALTH RELEVANCE: Retinitis Pigmentosa (RP) is an inherited disease of the eye that robs its victims of vision. While RD is a relatively rare disease, affecting approximately 100,000 people in the US, approximately 20% of children in schools for the blind suffer from RP. Clearly, the disastrous consequenc es of RP provide justification for intense research into the causes and potential therapies. Photoswitch Biosciences has developed a technology that has the potential to make healthy cells in the eye into cells that can receive and decode light, restoring sight to sufferers of RP.

Principal Investigator:

Andrew Blatz
6507732942
ANDY@PHOTOSWITCHBIO.COM

Business Contact:

Small Business Information at Submission:

PHOTOSWITCH BIOSCIENCES, INC.
PHOTOSWITCH BIOSCIENCES, INC. 1700 4TH ST, STE 218D SAN FRANCISCO, CA 94158

EIN/Tax ID: 135233921
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No